- Home
- AKTX
as 06-05-2025 4:00pm EST
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 29.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 11.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $4.40 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Akari Therapeutics plc ADS News
AKTX Breaking Stock News: Dive into AKTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
GlobeNewswire
15 days ago
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
GlobeNewswire
18 days ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
GlobeNewswire
22 days ago
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology
GlobeNewswire
a month ago
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala
GlobeNewswire
2 months ago
Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
MT Newswires
3 months ago
Akari Therapeutics Names Abizer Gaslightwala CEO
Compare AKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKTX Akari Therapeutics plc ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.